These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37176109)

  • 1. Gender-Specific Differences in Serum Sphingomyelin Species in Patients with Hepatitis C Virus Infection-Sphingomyelin Species Are Related to the Model of End-Stage Liver Disease (MELD) Score in Male Patients.
    Peschel G; Weigand K; Grimm J; Müller M; Krautbauer S; Höring M; Liebisch G; Buechler C
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection.
    Höring M; Peschel G; Grimm J; Krautbauer S; Müller M; Weigand K; Liebisch G; Buechler C
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection.
    Peschel G; Grimm J; Müller M; Höring M; Krautbauer S; Weigand K; Liebisch G; Buechler C
    Lipids Health Dis; 2022 Oct; 21(1):106. PubMed ID: 36280840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
    J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Phosphatidylcholine Species 32:0 as a Biomarker for Liver Cirrhosis Pre- and Post-Hepatitis C Virus Clearance.
    Weigand K; Peschel G; Grimm J; Höring M; Krautbauer S; Liebisch G; Müller M; Buechler C
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance.
    Peschel G; Krautbauer S; Weigand K; Grimm J; Höring M; Liebisch G; Müller M; Buechler C
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
    Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
    Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy.
    Weigand K; Peschel G; Grimm J; Müller M; Buechler C
    J Gastrointestin Liver Dis; 2022 Dec; 31(4):444-452. PubMed ID: 36535063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.
    Gambato M; Canini L; Lens S; Graw F; Perpiñan E; Londoño MC; Uprichard SL; Mariño Z; Reverter E; Bartres C; González P; Pla A; Costa J; Burra P; Cotler SJ; Forns X; Dahari H
    Liver Int; 2019 May; 39(5):826-834. PubMed ID: 30499631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.
    Choudhary NS; Saraf N; Saigal S; Rastogi A; Bhangui P; Thiagrajan S; Soin AS
    Indian J Gastroenterol; 2020 Dec; 39(6):539-543. PubMed ID: 33230754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum omentin-1 is correlated with the severity of liver disease in patients with chronic hepatitis C.
    Peschel G; Weigand K; Grimm J; Müller M; Buechler C
    World J Hepatol; 2023 Dec; 15(12):1315-1324. PubMed ID: 38223417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis.
    Pearlman BL
    Dig Dis Sci; 2024 May; 69(5):1551-1561. PubMed ID: 38580885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.
    Sandmann L; Dörge P; Wranke A; Vermehren J; Welzel TM; Berg CP; Grottenthaler JM; Weiss KH; Langel J; Sterneck M; von Wulffen M; Manns MP; Wedemeyer H; Hardtke S; von Hahn T
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1049-1056. PubMed ID: 30807443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients.
    Jain N; Garg R; Singh GP; Kaur S; Chawla SPS; Padda P
    Ann Afr Med; 2023; 22(4):456-464. PubMed ID: 38358146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.